Search
Tag: therapeutic plasma exchange
Inflammatory biomarkers in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease
TThis study from the AMBAR (Alzheimer Management by Albumin Replacement) phase 2b/3 trial examined the effects of plasma exchange with albumin replacement (PE-Alb) on…
Read More
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild‑to‑moderate Alzheimer’s disease: additional results from the AMBAR study
This study, part of the AMBAR phase 2b/3 clinical trial, investigated structural and functional brain changes in Alzheimer’s disease (AD) patients treated with therapeutic…
Read More
P57 Mapping Quality of Life – Alzheimer’s Disease (QOL-AD) Scores to EQ-5D-5L Utilities in the Ambar Trial Population
The AMBAR trial assessed the health-related quality of life (HRQoL) impact of plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease (AD) patients. Using…
Read More
Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer’s disease from the AMBAR study
The AMBAR trial studied the effects of plasma exchange (PE) on clinical laboratory parameters in Alzheimer’s disease (AD) patients. In this trial, 322 AD…
Read More
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study
This phase 2b/3 trial investigated the effects of plasma exchange (PE) with albumin replacement in patients with mild-to-moderate Alzheimer’s disease (AD). In the study,…
Read More
Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
The AMBAR (Alzheimer Management By Albumin Replacement) study is a multicenter, randomized, placebo-controlled phase IIb/III trial investigating the effects of plasma exchange (PE) with…
Read More
Results of Grifols’ AMBAR clinical trial published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
The results of Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) clinical trial, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show…
Read More
Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer’s Disease
Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) study results show that plasma exchange with albumin replacement significantly slows the progression of moderate Alzheimer’s disease….
Read More
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer’s disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
The 2021 AMBAR (Alzheimer’s Management by Albumin Replacement) study investigated the effects of plasma exchange (PE) with albumin replacement on neuropsychological, neuropsychiatric, and quality-of-life…
Read More